Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.

Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. Chronic Obstr Pulm Dis (2015) 1.43

Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation (2014) 1.18

Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest (2014) 1.15

Biomarkers of progression of chronic obstructive pulmonary disease (COPD). J Thorac Dis (2014) 1.14

Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014. Am J Respir Crit Care Med (2015) 1.12

Predictive role of hematologic parameters in testicular torsion. Korean J Urol (2015) 1.05

Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population. J Gen Intern Med (2014) 1.00

Compartment differences of inflammatory activity in chronic obstructive pulmonary disease. Respir Res (2014) 0.98

The relationship between inflammatory marker levels and pulmonary tuberculosis severity. Inflammation (2015) 0.96

Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study. J Transl Med (2014) 0.93

Relationships of pulmonary function, inflammation, and T-cell activation and senescence in an HIV-infected cohort. AIDS (2014) 0.91

The coexistence of common pulmonary diseases on the histologic type of lung cancer in both genders in Taiwan: a STROBE-compliant article. Medicine (Baltimore) (2014) 0.89

Predictors of exacerbations in chronic obstructive pulmonary disease--results from the Bergen COPD cohort study. PLoS One (2014) 0.88

Prognostic value of C-reactive protein, leukocytes, and vitamin d in severe chronic obstructive pulmonary disease. ScientificWorldJournal (2014) 0.84

The effects of pulmonary diseases on histologic types of lung cancer in both sexes: a population-based study in Taiwan. BMC Cancer (2015) 0.83

Growth Differentiation Factor-15 Is a Novel Biomarker Predicting Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Inflammation (2015) 0.83

Surfactant protein D, a clinical biomarker for chronic obstructive pulmonary disease with excellent discriminant values. Exp Ther Med (2016) 0.81

Systemic inflammation in predicting COPD exacerbations. JAMA (2013) 0.81

Application of nitric oxide measurements in clinical conditions beyond asthma. Eur Clin Respir J (2015) 0.80

The concept of control of COPD in clinical practice. Int J Chron Obstruct Pulmon Dis (2014) 0.80

Changes of HMGB1 and sRAGE during the recovery of COPD exacerbation. J Thorac Dis (2014) 0.80

Genetically Low Antioxidant Protection and Risk of Cardiovascular Disease and Heart Failure in Diabetic Subjects. EBioMedicine (2015) 0.80

The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. Int J Chron Obstruct Pulmon Dis (2015) 0.79

Will expanded ART use reduce the burden of HIV-associated chronic lung disease? Curr Opin HIV AIDS (2014) 0.79

Retrospective Assessment of Home Ventilation to Reduce Rehospitalization in Chronic Obstructive Pulmonary Disease. J Clin Sleep Med (2015) 0.79

Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease. Respir Res (2014) 0.79

Chest CT measures of muscle and adipose tissue in COPD: gender-based differences in content and in relationships with blood biomarkers. Acad Radiol (2014) 0.78

Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. Am J Respir Crit Care Med (2016) 0.78

Serum Metabolite Biomarkers Discriminate Healthy Smokers from COPD Smokers. PLoS One (2015) 0.78

C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations. J Pulm Respir Med (2016) 0.78

Lung function, respiratory symptoms and venous thromboembolism risk: the Atherosclerosis Risk in Communities Study. J Thromb Haemost (2016) 0.77

Preoperative plasma club (clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation. Am J Transplant (2014) 0.77

Proteoglycan 4 is a diagnostic biomarker for COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.77

Associations of pulmonary function with serum biomarkers and dialysis adequacy in patients undergoing peritoneal dialysis. Clin Exp Nephrol (2016) 0.77

The role of serum surfactant protein D as a biomarker of exacerbation of chronic obstructive pulmonary disease. Qatar Med J (2016) 0.76

Association of the Neutrophil-to-Lymphocyte Ratio with Lung Function and Exacerbations in Patients with Chronic Obstructive Pulmonary Disease. PLoS One (2016) 0.76

Comorbidity as a contributor to frequent severe acute exacerbation in COPD patients. Int J Chron Obstruct Pulmon Dis (2016) 0.75

Prognostic utility of admission cell-free DNA levels in patients with chronic obstructive pulmonary disease exacerbations. Int J Chron Obstruct Pulmon Dis (2016) 0.75

Potential prognostic value of biomarkers in lavage, sputum and serum in a five year clinical follow-up of smokers with and without COPD. BMC Pulm Med (2014) 0.75

Morbidity and Mortality in 7,684 Women According to Personal Hair Dye Use: The Copenhagen City Heart Study followed for 37 Years. PLoS One (2016) 0.75

A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.75

Factors associated with plasma IL-33 levels in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2017) 0.75

Inflammatory markers and mortality among US adults with obstructive lung function. Respirology (2015) 0.75

Frailty in Pulmonary and Critical Care Medicine. Ann Am Thorac Soc (2016) 0.75

Incidence of utilization- and symptom-defined COPD exacerbations in hospital- and population-recruited patients. Int J Chron Obstruct Pulmon Dis (2016) 0.75

Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study. NPJ Prim Care Respir Med (2017) 0.75

The Copenhagen City Heart Study (Østerbroundersøgelsen). Glob Cardiol Sci Pract (2015) 0.75

Inter-alpha-trypsin inhibitor heavy chain 4: a novel biomarker for environmental exposure to particulate air pollution in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.75

Airway gene expression of IL-1 pathway mediators predicts exacerbation risk in obstructive airway disease. Int J Chron Obstruct Pulmon Dis (2017) 0.75

COPD assessment test score and serum C-reactive protein levels in stable COPD patients. Int J Chron Obstruct Pulmon Dis (2016) 0.75

C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations. PLoS One (2017) 0.75

Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD. Respir Res (2017) 0.75

Risk factors for FEV1 decline in mild COPD and high-risk populations. Int J Chron Obstruct Pulmon Dis (2017) 0.75

PURLs: Should you consider antibiotics for exacerbations of mild COPD? J Fam Pract (2014) 0.75

Clinical characteristics of chronic bronchitic, emphysematous and ACOS phenotypes in COPD patients with frequent exacerbations. Int J Chron Obstruct Pulmon Dis (2017) 0.75

Acute exacerbations of COPD: risk factors for failure and relapse. Int J Chron Obstruct Pulmon Dis (2017) 0.75

A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respir Res (2017) 0.75

AHRR (cg05575921) hypomethylation marks smoking behaviour, morbidity and mortality. Thorax (2017) 0.75

Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D. PLoS One (2017) 0.75

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36

Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86

Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (2011) 9.07

Statin use and reduced cancer-related mortality. N Engl J Med (2012) 8.51

Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24

Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med (2008) 7.95

A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35

Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30

C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39

Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58

Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17

Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol (2012) 5.12

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54

A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA (2009) 4.42

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med (2014) 4.41

Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA (2008) 4.41

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35

Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19

Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med (2015) 4.16

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07

Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93

Short telomere length, cancer survival, and cancer risk in 47102 individuals. J Natl Cancer Inst (2013) 3.92

Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91

Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88

Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81

Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation (2013) 3.80

Skin cancer as a marker of sun exposure associates with myocardial infarction, hip fracture and death from any cause. Int J Epidemiol (2013) 3.73

Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70

C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 3.69

Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ (2011) 3.65

Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44

What is chronic obstructive pulmonary disease anyway?: Continua, categories, cut points, and moving beyond spirometry. Am J Respir Crit Care Med (2013) 3.39

Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med (2006) 3.27

Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med (2004) 3.25

Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20

Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol (2011) 3.19

Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA (2008) 3.10

Visible age-related signs and risk of ischemic heart disease in the general population: a prospective cohort study. Circulation (2013) 3.09

Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07

Genetic associations with valvular calcification and aortic stenosis. N Engl J Med (2013) 3.02

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00

Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med (2012) 3.00

Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med (2002) 2.95

Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med (2010) 2.94

Longevity in male and female joggers: the Copenhagen City Heart Study. Am J Epidemiol (2013) 2.89

Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88

FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J (2013) 2.87

Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest (2004) 2.86

Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med (2010) 2.80

An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care (2006) 2.74

Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72

Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med (2006) 2.65

Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol (2009) 2.61

A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation. COPD (2012) 2.60

'Highlights from this issue’ in the November issue of Thorax. Thorax (2013) 2.59

Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52

Integrin beta3 Leu33Pro homozygosity and risk of cancer. J Natl Cancer Inst (2003) 2.44

Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ (2013) 2.41

Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis (2012) 2.39

Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ (2012) 2.32

PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol (2010) 2.30

Extreme bilirubin levels as a causal risk factor for symptomatic gallstone disease. JAMA Intern Med (2013) 2.30

Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. Clin Chem (2010) 2.26

Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24

Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.21

Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest (2009) 2.20

Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation (2008) 2.19

C-reactive protein and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst (2010) 2.18

Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol (2002) 2.16

Plasma 25-hydroxyvitamin D, lung function and risk of chronic obstructive pulmonary disease. Thorax (2013) 2.15

Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality. Eur Urol (2013) 2.14

Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. J Am Coll Cardiol (2007) 2.13

Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension. Circulation (2004) 2.12

Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation (2007) 2.07

[Non-invasive ventilation in acute exacerbation of chronic obstructive pulmonary disease]. Ugeskr Laeger (2004) 2.03

Lipoprotein(a) and risk of type 2 diabetes. Clin Chem (2010) 2.01

Does greater adiposity increase blood pressure and hypertension risk?: Mendelian randomization using the FTO/MC4R genotype. Hypertension (2009) 2.01

Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.99

A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98